Bomb Report – Lifestyle
Author:
Deqi(Zhejiang)Pharmaceutical Technology Co. Ltd.
Antengene Presents Three Novel Programs at AACR 2026, Highlighting Next-Generation ADC and AnTenGager® TCEs
April 17, 2026
Antengene Announces 2025 Full-Year Results: First TCE Out-licensing Validates Platform Value and Marks Inflection Point Towards 2026 Profitability
March 20, 2026
Antengene to Present on Three Preclinical Programs at AACR 2026, Highlighting Next-Generation ADCs and AnTenGager™ TCEs
March 17, 2026
XPOVIO® Receives Reimbursement Approval in South Korea for a Second Multiple Myeloma Indication
March 6, 2026
Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb)
March 5, 2026